Key statistics
On Friday, Recordati Industria Chimica e Farmaceutica SpA (REC:MIL) closed at 48.18, 9.55% above its 52-week low of 43.98, set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 47.86 |
|---|---|
| High | 48.82 |
| Low | 47.78 |
| Bid | 47.90 |
| Offer | 48.80 |
| Previous close | 47.62 |
| Average volume | 360.83k |
|---|---|
| Shares outstanding | 209.13m |
| Free float | 111.21m |
| P/E (TTM) | 24.25 |
| Market cap | 9.96bn EUR |
| EPS (TTM) | 1.96 EUR |
| Annual div (ADY) | 1.30 EUR |
|---|---|
| Annual div yield (ADY) | 2.73% |
| Div ex-date | Nov 24 2025 |
| Div pay-date | Nov 26 2025 |
Data delayed at least 15 minutes, as of Feb 20 2026 16:37 GMT.
More ▼
- RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%
- RECORDATI ANNUNCIA SOLIDI RISULTATI PRELIMINARI PER L’ESERCIZIO 2025: RICAVI +11,8%, EBITDA(1) +14,5%, UTILE NETTO RETTIFICATO(2) +14,5%;
- RECORDATI ANNUNCIA UNA COLLABORAZIONE STRATEGICA CON MODERNA PER SVILUPPARE E COMMERCIALIZZARE A LIVELLO GLOBALE mRNA-3927 PER IL TRATTAMENTO DELL’ACIDEMIA PROPIONICA
- RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
- RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION
- RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER
- Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology
- RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%
- RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
- RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
More ▼
